Mark G. Perry
Derriford Hospital
15 Papers
50 Citations
Mark G. Perry is an academic researcher from Derriford Hospital. The author has contributed to research in topics: Medicine & Patient satisfaction. The author has an hindex of 7, co-authored 12 publications. Previous affiliations of Mark G. Perry include Bristol Royal Infirmary & National Health Service.
Chat about Author
Papers
Overnight variations in cortisol, interleukin 6, tumour necrosis factor α and other cytokines in people with rheumatoid arthritis
TL;DR: It is confirmed that there are abnormalities in plasma cortisol and IL6 concentrations and dynamics and the data also link the overnight rise in IL6 to the circadian variation in symptoms.
143
The Clinical Effectiveness of Patient Initiated Clinics for Patients with Chronic or Recurrent Conditions Managed in Secondary Care: A Systematic Review
TL;DR: The UK policy context is ripe for evidence-based, patient-centred services to be implemented, especially where the use of health care resources can be optimised without reducing the quality of care.
Alleviation of morning joint stiffness by low-dose prednisone in rheumatoid arthritis is associated with circadian changes in IL-6 and cortisol
Lynsey L. Clarke,Lynsey L. Clarke,David S. Jessop,Linda P. Hunt,Linda P. Hunt,Rainer H. Straub,Mark G. Perry,John R. Kirwan,John R. Kirwan +8 more
TL;DR: This study measured 24-h variations in IL-6, other cytokines and cortisol in patients before and after a 2-week course of night-time prednisone to address both the effect of Prednisone on the morning joint stiffness of rheumatoid arthritis and increased suppression of the hypothalamic–pituitary–adrenal axis.
28
Rates and predictors of methotrexate-related adverse events in patients with early rheumatoid arthritis: results from a nationwide UK study
Ahmad A Sherbini,James M. Gwinnutt,Adedeji David Adebajo,Khalid Ahmed,A G Al-Ansari,Roshan Amarasena,Marwan Bukhari,M. Callan,Easwaradhas G Chelliah,Hector Chinoy,Annie Cooper,Bhaskar Dasgupta,Martin Davis,James N. Galloway,Andrew Gough,Michael Green,Nicola J. Gullick,J. Hamilton,W Hassan,Samantha L. Hider,Kimme L. Hyrich,Sanjeet Kamath,Susan Knight,SE Lane,Martin Lee,Sarah Levy,Lizzy Macphie,C. Marguerie,Tom Marshall,Catherine J Mathews,Frank McKenna,Sophia M. Naz,Mark G. Perry,Louise C. Pollard,Brian Quilty,Lindsay Robertson,D.K. Roy,Paul Sanders,Vadivelu Saravanan,David Scott,Gillian L F Smith,Richard D. Smith,Deborah P M Symmons,Lee Suan Teh,N. Viner,Suzanne M M Verstappen +45 more
TL;DR: Prevalence rates and baseline predictors of adverse events (AEs) over the first year of treatment in patients with RA starting MTX were estimated to help patients make informed decisions whether to start MTX, potentially increasing adherence to treatment.
19